Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma

DISEASE CHARACTERISTICS:

Diagnosis of ocular melanoma

High-risk disease, defined by any of the following:

Large choroidal tumors with a basal diameter ≥ 16 mm and/or tumor thickness ≥ 10 mm (T3)
Extrascleral extension (T4)
Ciliary body involvement
Epithelioid cell type only
Have undergone appropriate primary treatment for ocular melanoma
No measurable metastatic disease

PATIENT CHARACTERISTICS:

ECOG performance status 0-2
ANC ≥ 1,200/mm³
Platelet count ≥ 100,000/mm³
Hemoglobin ≥ 9.0 g/dL
Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 50 mL/min
AST and ALT ≤ 3 times upper limit of normal
Pancreatic enzymes normal
Thyroid function normal or stable on replacement therapy
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
Cardiac ejection fraction ≥ 50% by MUGA or ECHO
No myocardial infarction within the past 6 months
No congestive heart failure requiring medication
No history of pulmonary disease requiring supplemental oxygen
No dyspnea at rest
No active infection
No chronic underlying immunodeficiency disease
No other serious illness that would preclude patient safety, in the opinion of the investigator
No other cancer within the past 5 years except nonmelanoma skin cancer or cervical cancer
No thromboembolic disease within the past 6 months

PRIOR CONCURRENT THERAPY:

No prior sunitinib malate, tamoxifen citrate, or cisplatin
No other concurrent chemotherapy, radiotherapy, or surgery